Active Transdermal Drug Delivery to 2018
|出版商||Greystone Research Associates||商品編碼||300588|
|積極的經皮藥物遞輸 Active Transdermal Drug Delivery to 2018|
|出版日期: 2014年05月01日||內容資訊: 英文||
The administration of therapeutic drugs via e advantages of transdermal drug delivery for improving patient compliance, particularly for the treatment of chronic conditions, are well known. But growth of transdermal delivery has been restricted by the need to limit candidate drugs to molecules small enough to effectively pass through the stratum corneum, a limitation that excludes passive transdermal patches as a viable option for the growing number of protein and peptide therapeutic compounds that will represent an increasing share of future NCEs. New technologies that employ energy or mechanical designs to affect drug transport through the skin are expanding the type and number of drug candidates that are viable for transdermal delivery. Evolving active transdermal systems will be well-positioned to address a significant segment of the large -molecule biological drugs expected to emerge from the convergence of automated discovery and genome mapping. As designs shrink in size and become more patient-friendly, opportunities for active transdermal delivery will increase.